A pilot study for discovering candidate genes of chromosome 18q21 in methamphetamine abusers: Case-control association study

Clinical Psychopharmacology and Neuroscience

Volumn 12, Issue 1, 2014, Pages 54-64

  Lee, Byung Dae ^a,b   Park, Je Min ^a,b   Lee, Young Min ^a,b   Moon, Eun Soo ^a,b   Jeong, Hee Jeong ^a,b   Chung, Young In ^a,b   Rim, Hyo Deog ^c  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

Author keywords

Comorbidity; Malic enzyme 2; Mapk4; Methamphetamine; Psychotic disorders; Substance related disorders

Indexed keywords

DNA; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE 4;

ADULT; ARTICLE; CHROMOSOME 18Q; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; INTRON; MALE; METHAMPHETAMINE DEPENDENCE; PILOT STUDY; POPULATION BASED CASE CONTROL STUDY; PSYCHOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84899544823     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2014.12.1.54     Document Type: Article

References (70)

1. McGuffin P, Asherson P, Owen M, Farmer A. The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry 1994;164:593-599. (Pubitemid 24161256)
2. Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005;32:173-202. (Pubitemid 41397185)
3. Bauer M, Unützer J, Pincus HA, Lawson WB; NIMH Affective Disorders Workgroup. Bipolar disorder. Ment Health Serv Res 2002;4:225-229. (Pubitemid 36032786)
4. Bartels SJ, Clark RE, Peacock WJ, Dums AR, Pratt SI. Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically ill patients. Am J Geriatr Psychiatry 2003;11:648-657. (Pubitemid 37392329)
5. Chung H, Park M, Hahn E, Choi H, Choi H, Lim M. Recent trends of drug abuse and drug-associated deaths in Korea. Ann N Y Acad Sci 2004;1025:458-464. (Pubitemid 39643894)
6. McKetin R, Kozel N, Douglas J, Ali R, Vicknasingam B, Lund J, et al. The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 2008;27:220-228.
7. Kulsudjarit K. Drug problem in southeast and southwest Asia. Ann N Y Acad Sci 2004;1025:446-457. (Pubitemid 39643893)
8. Rawson RA, Condon TP. Why do we need an Addiction supplement focused on methamphetamine? Addiction 2007; 102(Suppl 1):1-4. (Pubitemid 46328219)
9. Lapworth K, Dawe S, Davis P, Kavanagh D, Young R, Saunders J. Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. Addict Behav 2009;34:380-385.
10. Dore G, Sweeting M. Drug-induced psychosis associated with crystalline methamphetamine. Australas Psychiatry 2006; 14:86-89.
11. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al Methamphetamine Treatment Project. Psychiatric symptoms in methamphetamine users. Am J Addict 2004;13:181-190. (Pubitemid 38585698)
12. Buffenstein A, Heaster J, Ko P. Chronic psychotic illness from methamphetamine. Am J Psychiatry 1999;156:662.
13. Murray JB. Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol 1998;132:227-237. (Pubitemid 128469739)
14. Shih RA, Belmonte PL, Zandi PP. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. Int Rev Psychiatry 2004;16:260-283. (Pubitemid 39657837)
15. Van Broeckhoven C, Verheyen G. Report of the chromosome 18 workshop. Am J Med Genet 1999;88:263-270. (Pubitemid 29269493)
16. Pulver AE, Mulle J, Nestadt G, Swartz KL, Blouin JL, Dombroski B, et al. Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes. Mol Psychiatry 2000;5:650-653.
17. Siris SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry 2000;157:1379-1389.
18. Bailer U, Leisch F, Meszaros K, Lenzinger E, Willinger U, Strobl R, et al. Genome scan for susceptibility loci for schizophrenia and bipolar disorder. Biol Psychiatry 2002; 52:40-52. (Pubitemid 34655555)
19. Cardno AG, Rijsdijk FV, Sham PC, Murray RM, McGuffin P. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry 2002;159:539-545. (Pubitemid 34274934)
20. Potash JB, Zandi PP, Willour VL, Lan TH, Huo Y, Avramopoulos D, et al. Suggestive linkage to chromosomal regions 13q31 and 22q12 in families with psychotic bipolar disorder. Am J Psychiatry 2003;160:680-686. (Pubitemid 41079600)
21. Berrettini W. Bipolar disorder and schizophrenia: convergent molecular data. Neuromolecular Med 2004;5:109-117. (Pubitemid 38391960)
22. Walss-Bass C, Escamilla MA, Raventos H, Montero AP, Armas R, Dassori A, et al. Evidence of genetic overlap of schizophrenia and bipolar disorder: linkage disequilibrium analysis of chromosome 18 in the Costa Rican population. Am J Med Genet B Neuropsychiatr Genet 2005;139B:54-60. (Pubitemid 41552299)
23. Escamilla M, Lee BD, Ontiveros A, Raventos H, Nicolini H, Mendoza R, et al. The epsin 4 gene is associated with psychotic disorders in families of Latin American origin. Schizophr Res 2008;106:253-257.
24. Escamilla MA. Population isolates: their special value for locating genes for bipolar disorder. Bipolar Disord 2001;3:299-317. (Pubitemid 34072001)
25. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 1996;67:473-477.
26. Kim EY, Kwon do H, Lee BD, Kim YT, Ahn YB, Yoon KY, et al. Frequency of osteoporosis in 46 men with methamphetamine abuse hospitalized in a National Hospital. Forensic Sci Int 2009;188:75-80.
27. Lee BD, Walss-Bass C, Thompson PM, Dassori A, Montero PA, Medina R, et al. Malic enzyme 2 and susceptibility to psychosis and mania. Psychiatry Res 2007;150:1-11. (Pubitemid 46281340)
28. Broman KW, Murray JC, Sheffield VC, White RL, Weber JL. Comprehensive human genetic maps: individual and sex-specific variation in recombination. Am J Hum Genet 1998;63:861-869. (Pubitemid 30422687)
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
30. Hassel B. Pyruvate carboxylation in neurons. J Neurosci Res 2001;66:755-762.
31. Uhl GR, Drgon T, Johnson C, Fatusin OO, Liu QR, Contoreggi C, et al. "Higher order" addiction molecular genetics: convergent data from genome-wide association in humans and mice. Biochem Pharmacol 2008;75:98-111. (Pubitemid 350235391)
32. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849-859; discussion 863-864.
33. Tuck SP, Datta HK. Osteoporosis in the aging male: treatment options. Clin Interv Aging 2007;2:521-536.
34. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008;27:535-545. (Pubitemid 351225684)
35. Yaegashi Y, Onoda T, Tanno K, Kuribayashi T, Sakata K, Orimo H. Association of hip fracture incidence and intake of calcium, magnesium, vitamin D, and vitamin K. Eur J Epidemiol 2008;23:219-225.
36. Mazziotti G, Giustina A, Canalis E, Bilezikian JP. Gluco-corticoid- induced osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metabol 2007;51:1404-1412.
37. Blahos J. Treatment and prevention of osteoporosis. Wien Med Wochenschr 2007;157:589-592.
38. Migliaccio S, Brama M, Fornari R, Greco EA, Spera G, Malavolta N. Glucocorticoid-induced osteoporosis: an osteoblastic disease. Aging Clin Exp Res 2007;19(3 Suppl):5-10.
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (text revision). Washington DC: American Psychiatric Association; 1996.
40. Weber JL, Wong C. Mutation of human short tandem repeats. Hum Mol Genet 1993;2:1123-1128. (Pubitemid 23244988)
41. Weir BS. Genetic Data Analysis II: Methods for discrete population genetic data. Sunderland, MA: Sinauer Associates; 1996.
42. Draǎghici S. Data analysis tools for DNA microarrays. Boca Raton: Chapman & Hall/CRC; 2003.
43. Korean Statistical Information Service (KOSIS). Census of the Korean population by administrative distinct, sex and age [Internet]. Office KNS, 2004. Available from http://kosis.kr/
44. Maurer I, Zierz S, Müller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 2001;48:125-136. (Pubitemid 32241188)
45. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 2002;22:2718-2729. (Pubitemid 37465821)
46. Bubber P, Tang J, Haroutunian V, Xu H, Davis KL, Blass JP, et al . Mitochondrial enzymes in schizophrenia. J Mol Neurosci 2004;24:315-321. (Pubitemid 41359159)
47. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004;61:300-308. (Pubitemid 38295832)
48. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004;9:684-697, 643.
49. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005;14:241-253.
50. Escamilla MA, McInnes LA, Service SK, Spesny M, Reus VI, Molina J, et al. Genome screening for linkage disequilibrium in a Costa Rican sample of patients with bipolar-I disorder: a follow-up study on chromosome 18. Am J Med Genet 2001;105:207-213. (Pubitemid 32290588)
51. Williams NM, Rees MI, Holmans P, Norton N, Cardno AG, Jones LA, et al. A two-stage genome scan for schizophrenia susceptibility genes in 196 affected sibling pairs. Hum Mol Genet 1999;8:1729-1739. (Pubitemid 29423883)
52. Ewald H, Mors O, Koed K, Eiberg H, Kruse TA. Susceptibility loci for bipolar affective disorder on chromosome 18? A review and a study of Danish families. Psychiatr Genet 1997;7:1-12. (Pubitemid 27356814)
53. Maziade M, Roy MA, Rouillard E, Bissonnette L, Fournier JP, Roy A, et al. A search for specific and common susceptibility loci for schizophrenia and bipolar disorder: a linkage study in 13 target chromosomes. Mol Psychiatry 2001;6:684-693. (Pubitemid 33020588)
54. Ohki I, Shimotake N, Fujita N, Jee J, Ikegami T, Nakao M, et al. Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell 2001;105:487-497. (Pubitemid 32520854)
55. Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, Cuccaro ML, et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr Neurol 2003;28:205-211. (Pubitemid 36593431)
56. Greenberg DA, Cayanis E, Strug L, Marathe S, Durner M, Pal DK, et al. Malic enzyme 2 may underlie susceptibility to adolescent-onset idiopathic generalized epilepsy. Am J Hum Genet 2005;76:139-146.
57. Itoh S, Itoh F, Goumans MJ, Ten Dijke P. Signaling of transforming growth factor-beta family members through Smad proteins. Eur J Biochem 2000;267:6954-6967. (Pubitemid 32009435)
58. Lu J, Wu Y, Sousa N, Almeida OF. SMAD pathway mediation of BDNF and TGF beta 2 regulation of proliferation and differentiation of hippocampal granule neurons. Development 2005;132:3231-3242. (Pubitemid 41167151)
59. Gonzalez FA, Raden DL, Rigby MR, Davis RJ. Heterogeneous expression of four MAP kinase isoforms in human tissues. FEBS Lett 1992;304:170-178.
60. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663-675.
61. Li L, Wysk M, Gonzalez FA, Davis RJ. Genomic loci of human mitogen-activated protein kinases. Oncogene 1994;9:647-649. (Pubitemid 24041545)
62. García JI, Zalba G, Detera-Wadleigh SD, de Miguel C. Isolation of a cDNA encoding the rat MAP-kinase homolog of human p63mapk. Mamm Genome 1996;7:810-814. (Pubitemid 126440454)
63. New L, Jiang Y, Zhao M, Liu K, Zhu W, Flood LJ, et al. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J 1998;17:3372-3384. (Pubitemid 28279511)
64. Ni H, Wang XS, Diener K, Yao Z. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. Biochem Biophys Res Commun 1998;243:492-496. (Pubitemid 28414052)
65. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68:320-344. (Pubitemid 38756868)
66. Gaestel M. MAPKAP kinases- MKs -two's company, three's a crowd. Nat Rev Mol Cell Biol 2006;7:120-130. (Pubitemid 43278295)
67. Schumacher S, Laass K, Kant S, Shi Y, Visel A, Gruber AD, et al. Scaffolding by ERK3 regulates MK5 in development. EMBO J 2004;23:4770-4779. (Pubitemid 40069707)
68. Seternes OM, Mikalsen T, Johansen B, Michaelsen E, Armstrong CG, Morrice NA, et al. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J 2004;23:4780-4791. (Pubitemid 40069708)
69. Liu QR, Drgon T, Johnson C, Walther D, Hess J, Uhl GR. Addiction molecular genetics: 639,401 SNP whole genome association identifies many "cell adhesion" genes. Am J Med Genet B Neuropsychiatr Genet 2006;141B:918-925. (Pubitemid 44905448)
70. Straub RE, Sullivan PF, Ma Y, Myakishev MV, Harris-Kerr C, Wormley B, et al. Susceptibility genes for nicotine dependence: a genome scan and followup in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17 and 18 merit further study. Mol Psychiatry 1999;4:129-144. (Pubitemid 29163976)